Covered recipient · General Payments record
NAZIF A CHOWDHURY
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
General Payments · PY2018–2024
$1,476.47
- Reported across 68 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $389.44 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $167.47 | 9 |
| Gilead Sciences, Inc. | $108.88 | 4 |
| GENZYME CORPORATION | $86.77 | 3 |
| AIMMUNE THERAPEUTICS, INC. | $26.32 | 2 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $20.91 | 01/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103468797 | CMS |
| ABBVIE INC. | $17.36 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103468799 | CMS |
| ABBVIE INC. | $12.05 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103468801 | CMS |
| ABBVIE INC. | $25.54 | 04/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103468803 | CMS |
| ABBVIE INC. | $21.35 | 04/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103468805 | CMS |
| ABBVIE INC. | $1.88 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103468807 | CMS |
| ABBVIE INC. | $27.40 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103468809 | CMS |
| ABBVIE INC. | $26.96 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103468811 | CMS |
| ABBVIE INC. | $14.02 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103468813 | CMS |
| AIMMUNE THERAPEUTICS, INC. | $13.16 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146964221 | CMS |
| AIMMUNE THERAPEUTICS, INC. | $13.16 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146976050 | CMS |
| GENZYME CORPORATION | $28.78 | 03/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139981704 | CMS |
| GENZYME CORPORATION | $31.42 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139981720 | CMS |
| GENZYME CORPORATION | $26.57 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139981724 | CMS |
| Gilead Sciences, Inc. | $29.56 | 01/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133780024 | CMS |
| Gilead Sciences, Inc. | $21.06 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133780026 | CMS |
| Gilead Sciences, Inc. | $27.94 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133780028 | CMS |
| Gilead Sciences, Inc. | $30.32 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133780030 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.